Cannasouth Limited is the parent company and 100% owner of subsidiary companies:
- Cannasouth Bioscience Limited
- Cannasouth Cultivation Ltd
- Eqalis Group New Zealand Ltd, comprising;
- Eqalis Pharmaceuticals Ltd
- Eqalis Innovations Ltd
- RestoreMe Clinic Ltd
The Cannasouth Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds such as CBD, THC and associated chemical structures that are produced by the cannabis plant. Our goal is the development of next-generation cannabinoid medicines that support patients’ health outcomes and improve their quality of life.
Cannasouth merged with Bay of Plenty based Eqalis Group New Zealand Ltd, effective 1 June 2023. With end-to-end GMP certification, starting with the production of dried cannabis flower, through to the manufacture of cannabis-based ingredients and medicinal cannabis products (oral solutions), we are in a strong position to fulfil market demands for New Zealand and globally. Our products are produced under GxP using environmentally friendly methods without the use of harmful chemicals or solvents, ensuring patients are treated with pure cannabinoid therapeutic compounds of the highest quality.
Cannasouth has a range of verified products including;
- a cannabis-based ingredient,
- oral solutions, and
- the first flower to be entirely grown, dried, processed and packed in New Zealand.
New Registered Office Address:
Level 2, CRV Building
Waikato Innovation Park
2 Melody Lane
Hamilton East, 3216
Phone: +64 7 949 8393
Financial Year End: December 31 each year